Literature DB >> 19328743

Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome.

Lone Schejbel1, Vibeke Rosenfeldt, Hanne Marquart, Niels Henrik Valerius, Peter Garred.   

Abstract

Properdin is an initiator and stabilizer of the alternative complement activation pathway (AP). Deficiency of properdin is a rare X-linked condition characterized by increased susceptibility to infection with Neisseria meningitidis associated with a high mortality rate. We report properdin deficiency in a large Pakistani family. The index cases were found by screening for immunodeficiency due to a history of recurrent infections. This revealed absent AP activity, but normal classical and lectin pathway activity. Sequencing of the properdin gene (PFC) revealed a novel frameshift mutation. When all available relatives (n=24) were screened for the mutation, four affected males, four female carriers and a male heterozygous carrier were identified. He was subsequently diagnosed with Klinefelter syndrome. A questionnaire revealed a striking association between properdin deficiency and recurrent otitis media (P=0.0012), as well as recurrent pneumonia (P=0.0017). This study is the first to show a significant association between properdin deficiency and recurrent infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328743     DOI: 10.1016/j.clim.2009.02.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

2.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

Review 3.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  A novel mutation W388X underlying properdin deficiency in a Finnish family.

Authors:  M Helminen; S Seitsonen; H Jarva; S Meri; I E Järvelä
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

5.  Functional analysis of Ficolin-3 mediated complement activation.

Authors:  Estrid Hein; Christian Honoré; Mikkel-Ole Skjoedt; Lea Munthe-Fog; Tina Hummelshøj; Peter Garred
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

6.  X-Linked agammaglobulinemia in a child with Klinefelter's syndrome.

Authors:  Alexis-Virgil Cochino; Ales Janda; Barbora Ravcukova; Vasilica Plaiasu; Diana Ochiana; Ioan Gherghina; Tomas Freiberger
Journal:  J Clin Immunol       Date:  2014-01-30       Impact factor: 8.317

7.  Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.

Authors:  Damodar Gullipalli; Fengkui Zhang; Sayaka Sato; Yoshiyasu Ueda; Yuko Kimura; Madhu Golla; Takashi Miwa; Jianxiang Wang; Wen-Chao Song
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

8.  Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection.

Authors:  Youssif Mohammed Ali; Azam Hayat; Bayad Mawlood Saeed; Kashif S Haleem; Saleh Alshamrani; Hany I Kenawy; Viviana P Ferreira; Gurpanna Saggu; Anna Buchberger; Peter J Lachmann; Robert B Sim; Dimitrios Goundis; Peter W Andrew; Nicholas J Lynch; Wilhelm J Schwaeble
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

9.  Risk factors for chronic and recurrent otitis media-a meta-analysis.

Authors:  Yan Zhang; Min Xu; Jin Zhang; Lingxia Zeng; Yanfei Wang; Qing Yin Zheng
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.